Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 198

Similar articles for PubMed (Select 12843794)

1.

LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors.

Li J, Hu P, Khawli LA, Epstein AL.

J Immunother. 2003 Jul-Aug;26(4):320-31.

PMID:
12843794
2.
3.

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.

Khawli LA, Hu P, Epstein AL.

Handb Exp Pharmacol. 2008;(181):291-328. Review.

PMID:
18071951
4.

Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.

Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL.

Hybrid Hybridomics. 2003 Aug;22(4):197-207.

PMID:
14511565
5.

chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors.

Li J, Hu P, Khawli LA, Yun A, Epstein AL.

Hybrid Hybridomics. 2004 Feb;23(1):1-10.

PMID:
15000842
6.

Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.

Hornick JL, Sharifi J, Khawli LA, Hu P, Bai WG, Alauddin MM, Mizokami MM, Epstein AL.

J Nucl Med. 2000 Feb;41(2):355-62.

7.

B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.

Liu A, Hu P, Khawli LA, Epstein AL.

J Immunother. 2006 Jul-Aug;29(4):425-35.

PMID:
16799338
8.

Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).

Biela BH, Khawli LA, Hu P, Epstein AL.

Cancer Biother Radiopharm. 2003 Jun;18(3):339-53.

PMID:
12954121
9.
10.

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.

Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL.

Clin Cancer Res. 2007 May 1;13(9):2758-67. Epub 2007 Apr 25.

11.

Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells.

Khawli LA, Biela BH, Hu P, Epstein AL.

Hybrid Hybridomics. 2002 Feb;21(1):11-8.

PMID:
11991812
12.

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.

Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.

Clin Cancer Res. 2005 Aug 1;11(15):5566-71.

13.

A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors.

Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, Yun A, Taylor CR, Epstein AL.

Cancer Biother Radiopharm. 1998 Aug;13(4):255-68.

PMID:
10850361
14.

Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.

Clin Cancer Res. 2009 Jul 15;15(14):4612-21. doi: 10.1158/1078-0432.CCR-08-3321. Epub 2009 Jul 7.

15.

Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes.

Pan H, Han L, Chen W, Yao M, Lu W.

J Control Release. 2008 Feb 11;125(3):228-35. Epub 2007 Oct 26.

PMID:
18022270
16.

Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.

Hisada M, Yoshimoto T, Kamiya S, Magami Y, Miyaji H, Yoneto T, Tamada K, Aoki T, Koyanagi Y, Mizuguchi J.

Cancer Gene Ther. 2004 Apr;11(4):280-8.

PMID:
15002032
17.

Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses.

Shi M, Hao S, Su L, Zhang X, Yuan J, Guo X, Zheng C, Xiang J.

Cancer Biother Radiopharm. 2005 Aug;20(4):401-9.

PMID:
16114988
18.

Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S.

Clin Cancer Res. 2004 Apr 15;10(8):2891-901.

19.

Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.

Flanagan K, Glover RT, Hörig H, Yang W, Kaufman HL.

Vaccine. 2004 Jul 29;22(21-22):2894-903.

PMID:
15246626
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk